SCHEMBL4845923

SCHEMBL4845923

CCOC[C@@H](NC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 6/20 0.58
PPARG P37231 5/20 0.55
CTSS P25774 7/20 0.50
CTSK P43235 7/20 0.50
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
HTT P42858 1/20 0.47
CTSL P07711 1/20 0.44
CTSB P07858 1/20 0.44
ACE P12821 1/20 0.44
PPARD Q03181 2/20 0.43
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CAPN1 P07384 1/20 0.42
IDO1 P14902 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL954493 1.00 PPARA (0.58) PPARAPPARGCTSSCTSKCYP1A2
SCHEMBL1987227 1.00 PPARA (0.58) PPARAPPARGCTSSCTSKCYP1A2
SCHEMBL21837472 0.87 PPARA (0.55) PPARAPPARGCTSSCTSKCYP1A2
SCHEMBL21837471 0.87 PPARA (0.55) PPARAPPARGCTSSCTSKCYP1A2
SCHEMBL24633954 0.87 PPARA (0.55) PPARAPPARGCTSSCTSKCYP1A2
SCHEMBL16170321 0.87 CYP1A2 (0.47) PPARAPPARGCTSSCTSKCYP1A2
SCHEMBL14842431 0.85 CYP1A2 (0.49) PPARAPPARGCTSSCTSKCYP1A2
SCHEMBL14842430 0.85 CYP1A2 (0.49) PPARAPPARGCTSSCTSKCYP1A2
SCHEMBL25892128 0.85 PPARA (0.56) PPARAPPARGCTSSCTSKCTSL
SCHEMBL13897471 0.85 PPARA (0.56) PPARAPPARGCTSSCTSKCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140309225-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2014-10-16 US disclosed
US-7384934-B2 Piperazine substituted aryl benzodiazepines ELI LILLY AND COMPANY (US) 2008-06-10 US disclosed
EP-1546134-B1 PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES LILLY CO ELI (US) 2007-05-02 EP disclosed
US-20060084643-A1 Piperazine substituted aryl benzodiazepines ELI LILLY AND COMPANY 2006-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084643-A1 Piperazine substituted aryl benzodiazepines GABBR1, GABBR2, GABRA5 PPARA 405/4885PPARG 148/4885CTSS 4323/4885
US-20140309225-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF SYK, BTK, NOX4 PPARA 1363/4885PPARG 1929/4885CTSS 4028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.